Background. Genital herpes is an important cofactor for acquisition of human immunodeficiency virus (HIV) infection, and effective prophylaxis is a helpful strategy to halt both HIV and herpes simplex virus (HSV) transmission. The antiretroviral agent tenofovir, formulated as a vaginal microbicide gel, was shown to reduce the risk of HIV and HSV type 2 (HSV-2) acquisition.
Herpes simplex virus (HSV) is a common cause of both genital and oral diseases. HSV type 2 (HSV-2) is mostly sexually transmitted whereas HSV type 1 (HSV-1) is frequently acquired during early childhood, mainly via oral secretions. However, the epidemiology of HSV is changing, with increased frequency of HSV-1 sexual transmission [1] [2] [3] . Genital herpes is an important cofactor for human immunodeficiency virus (HIV) acquisition, and preexposure prophylaxis (PrEP) is a helpful strategy to halt both HIV and HSV transmission [4] [5] [6] .
The acyclic nucleoside phosphonate (ANP) tenofovir (TFV), an effective inhibitor of HIV reverse transcriptase, is one of the most commonly used antiretroviral drugs, administered orally under its prodrug form tenofovir disoproxil fumarate (TDF) alone or in fixed-dose combinations. Recently, a newer prodrug of TFV, tenofovir alafenamide, with greater antiviral activity and better distribution into lymphoid tissues than TDF was approved [7] .
TFV has also been evaluated for prevention of HIV and HSV-2 infections. The CAPRISA 004 study (first trial to evaluate TFV as a microbicide) [8] showed that a 1% TFV vaginal microbicide gel provided an overall protective effect of 39% against HIV acquisition and 51% against HSV-2 infection [8, 9] . However, the VOICE study that evaluated oral TFV alone and in combination with emtricitabine and TFV vaginal gel, was stopped early due to inability to demonstrate efficacy [10] . This negative outcome was mainly explained by the low adherence [11] . The FACTS 001 trial showed that pericoital vaginal TFV 1% gel was not effective in preventing HIV acquisition. An impact of oral TFV on HSV-2 or HSV-1 shedding rates was not observed in asymptomatic individuals coinfected with HIV and HSV [12] . The PEARLS A5175 study showed that HSV-2 acquisition was not reduced in HIV-infected/HSV-uninfected adults treated with TDF as part of combination antiretroviral therapy [13] . However, daily oral TFV and emtricitabine-TFV PrEP reduced HIV and HSV-2 acquisition among heterosexual HIV-1-uninfected men and women (who were at risk for HIV-1 acquisition due to having an HIV-1-infected partner) [14, 15] .
The inconsistent results from clinical protocols using TFVbased regimens in PrEP have been primarily explained by poor adherence. Though inadequate drug concentrations at the site of infection (the genital tract) as well as integrity of the vaginal epithelium may be involved [11, 16] , differences in TFV activation in peripheral blood mononuclear cells, vaginal, and colorectal tissues due to variance in nucleotide kinase expression and activity were reported [17, 18] . Furthermore, genetic variants of the kinases that phosphorylate TFV could affect its activation, influencing drug efficacy.
TFV has been known as a highly potent antiretroviral drug with minimal anti-HSV activity [19] . However, TFV proved direct antiherpetic activity at the concentration achieved intravaginally with a 1% TFV topical gel [16] . Topical application of 1% TFV gel on the genital mucosa resulted in TFV concentrations of up to 350 μg/mL in vaginal fluid, which is above the 50% effective concentration (EC 50 ) against both HSV-1 and HSV-2 [20] . Furthermore, the active TFV metabolite (TFV-diphosphate) inhibited both HSV DNA polymerase (pol) and HIV reverse transcriptase activities in enzymatic assays [20] . However, because of the poor activity of TFV against HSV, concerns have been raised regarding its selectivity and specificity as an anti-HSV agent.
In an effort to develop a compound highly potent against both HIV and HSV-2, we identified PMEO-DAPy (6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine) [21] . This compound demonstrated potent anti-HIV and -HSV activity in clinically relevant in vitro, ex vivo, and in vivo systems. However, in striking contrast to TFV, PMEO-DAPy also acts as an efficient immunomodulator without the need of intracellular metabolism [21] .
To prove definitively that TFV and PMEO-DAPy target the HSV DNA pol, we have now selected and characterized phenotypically and genotypically viral mutants emerging under pressure with both drugs. In addition, well-characterized laboratory-or clinic-derived DNA pol mutants have been evaluated for their sensitivity to TFV and PMEO-DAPy.
METHODS

Cells and Viruses
Human embryonic lung (HEL) fibroblasts (ATCC CCL-137) were maintained in minimum essential medium supplemented with 10% heat-inactivated fetal calf serum. HEL cells were used for production of viral stocks, selection of drug-resistant viruses, and antiviral assays.
The HSV-1 reference strain Kos (ATCC VR-1493), the HSV-2 reference strain G (ATCC VR-734) and several drug-resistant clinical strains were used.
Isolation of Drug-Resistant Viruses
HEL cells were seeded in 25-cm 2 flasks and infected with the reference HSV strains in the presence of TFV or PMEO-DAPy starting at a concentration equivalent to the EC 50 . For HSV-2, mutants were also selected under pressure with 2-phosphonylmethoxyethyl (PME) derivatives of adenine (PMEA, adefovir) and 2,6-diaminopurine (PMEDAP). When full cytopathic effect was reached, samples were frozen and the virus was harvested and used to infect cells for the next passage. This process was repeated several times in increasing concentrations of the compound. Each drug-resistant virus was passaged 2 or 3 times in the highest drug concentration (TFV 400 µg/mL, PMEA 200 µg/mL, PMEDAP, and PMEO-DAPy 50 µg/mL) and further cultured for 1 additional passage in drug-free medium. Several drug-resistant clones were then isolated and tested for their drug sensitivity.
Antiviral Assays
The drug susceptibilities of the different virus clones were determined by cytopathic effect reduction assays in HEL cell cultures as previously described [22, 23] . For each viral mutant, at least 3-6 independent phenotypic assays were performed and the mean EC 50 values were calculated. HSV isolates were considered resistant at ≥2-fold increase in EC 50 .
Genotypic Antiviral Resistance Testing
Viral DNA was extracted from clinical isolates and laboratory-derived strains or plaque-purified viruses by using a QIAamp DNA blood mini kit (Qiagen). A set of 8 M13-labeled primers were used for gene amplification of the full-length UL30 (DNA pol) gene (3708 bp for HSV-1 and 3723 bp for HSV-2). Polymerase chain reaction (PCR) was performed using the proofreading Faststart High Fidelity PCR System kit (Sigma) and amplified products were purified with the QIAquick PCR Purification Kit (Qiagen). The amplicons were sequenced with the BigDye Terminator version 3.1 sequencing kit (ThermoFisher Scientific) and analyzed with the automated sequencer ABI 3730 genetic analyzer (Applied Biosystems). All nucleotide and amino acid sequencing results were compared with the reference strains Kos (HSV-1) and G (HSV-2) using Seqscape version 2.7 software.
RESULTS
Genotyping of Drug-Resistant TFV and PMEO-DAPy Viruses Compared to
Other Anti-HSV Drugs and Relationship With Previously Described HSV
DNA Pol Mutations
To undoubtedly determine that the HSV DNA pol is the target of TFV, we selected TFV-resistant (TFV-R) HSV-1 and HSV-2 mutants and genotyped the UL30 gene. Three (HSV-1) and 2 (HSV-2) independent procedures of selection with TFV were performed. All HSV-1 TFV-R plaque purified viruses harbored the L802F amino acid change in the viral DNA pol while all HSV-2 TFV-R clones had the A724V mutation ( Table 1 ). The HSV-1 DNA pol L802F change has been previously described in viruses selected in vitro for PMEA resistance [22] , whereas the A724V substitution has been associated with acyclovir/foscarnet resistance both in vitro and in the clinic [24, 25] .
HSV-1 PMEO-DAPy-resistant (PMEO-DAPy-R) viruses presented the A719V (1 clone) or the S724N (4 clones) substitutions. Both mutations have been reported in clinical strains associated with failure to acyclovir and foscarnet treatment [26, 27] and have been selected in vitro under pressure with foscarnet (A719V and S724N) and the PME derivatives (S724N) [22, 23] . In the case of HSV-2 PMEO-DAPy-R viruses, all 4 clones presented the M789T.
Because no data were available for HSV-2 PMEA-R and PMEDAP-R viruses, we genotyped clones isolated following pressure with these 2 drugs ( Table 1 ). Similar to PMEODAPy-R viruses, all HSV-2 clones selected under PMEA had the M789T substitution. Two different substitutions (M789T and A724V) associated with drug resistance were identified in PMEDAP-R clones. Figure 1 shows the location of the mutations emerging under the PME derivatives compared to those arising under TFV and PMEO-DAPy.
Phenotyping of Drug-Resistant TFV and PMEO-DAPy Viruses
We then examined the drug susceptibility profile of TFV-R and PMEO-DAPy-R viruses bearing specific DNA pol mutations. L802F, A719V, and S724N (HSV-1) and A724V and M789T (HSV-2) were associated with TFV-R when using a cutoff value of ≥2-fold change in EC 50 values (Figure 2 ). The highest levels of resistance to TFV were measured for the HSV-1 S724N and A719V mutants (≥5-fold increase in EC 50 values) and for the HSV-2 A724V mutant (≥4.4-fold increase in EC 50 value). The HSV-2 M789T and the HSV-1 L802F substitutions conferred, respectively, ≥2.3-and ≥3.7-fold resistance to TFV. These mutants were also resistant to PMEO-DAPy (3.7-to 22.5-fold increase in EC 50 value), the PME derivatives, and foscarnet. A 3.2-to 4.5-fold decrease in susceptibility to acyclovir was measured for the TFV-R and PMEO-DAPy-R viruses, and no cross-resistance with 
For tenofovir, 2 (HSV-2) or 3 (HSV-1) independent procedures of selection (designated A, B, and C) were performed. For each selection procedure, 1 (HSV-1 clone A-5), 2 (HSV-1: clones B-1, B-2, C-1, and C-2; HSV-2: clones A-1 and A-2) and 5 (HSV-2: clones C-1, C-2, C-3, C-4, and C-5) clones were analyzed. Thus, the L802F (HSV-1) and the A724V (HSV-2) DNA pol substitutions independently emerged 3 and 2 times, respectively. In the case of PMEA, PMEDAP, and PMEO-DAPy, a single selection procedure was performed and then several clones were analyzed.
Abbreviations: HSV, herpes simplex virus; PMEO-DAPy, 6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine; PMEA, 2-phosphonylmethoxyethyl derivative of adenine; PMEDAP, 2-phosphonylmethoxyethyl derivative of 2,6-diaminopurine; TFV, tenofovir.
a Novel amino acid change not associated with drug resistance.
brivudine or ganciclovir was registered. In the case of penciclovir and cidofovir, no cross-resistance or low levels of resistance were measured (1.6-to 2.6-fold [penciclovir] and 1.6-to 2.8-fold [cidofovir] increase in EC 50 values).
Relevant TFV and PMEO-DAPy Resistance Mutations Exist in the Clinic
We have previously reported that thymidine kinase (TK) HSV-1 and HSV-2 mutants remained sensitive to both TFV and PMEO-DAPy [20, 21] . We have now evaluated several clinical strains (recovered from patients who failed antiherpesvirus therapy with acyclovir and/or foscarnet in the context of our translational research platform RegaVir, www.regavir.org) that bear alterations in the viral DNA pol gene. Well-characterized clinical isolates of HSV-1 (5) and HSV-2 (18) with specific substitutions in the viral DNA pol as well as 7 laboratory-derived strains (6 for HSV-1 and 1 for HSV-2) were assessed (Tables  2 and 3 ). All DNA pol mutants proved resistant to TFV and PMEO-DAPy and to the PME derivatives. Except for the Q618H (HSV-1) and the N815S (homologous to the HSV-2 N820S) mutants, cross-resistance with the pyrophosphate analogue foscarnet was found. While all tested DNA pol mutants proved also acyclovir resistant, not all of them had decreased sensitivity to penciclovir. Importantly, the HSV-1 N815S mutant and the corresponding HSV-2 N820S showed the highest levels of resistance to acyclovir and penciclovir and were the only mutants presenting low levels of ganciclovir resistance. Strikingly, these mutants demonstrated hypersensitivity to foscarnet. With the exception of the S724N and L802F (HSV-1) and the I731F (HSV-2) mutants that had a 2.3-to 2.8-fold decrease in EC 50 for cidofovir, all other mutants remained sensitive to this nucleotide analogue. Data for brivudine are only provided for HSV-1, as this compound exhibits very low potency against HSV-2 due to a lack of conversion of the monophosphate brivudine to the diphosphate (DP) form by the HSV-2 TK, which is deprived deoxythymidylate kinase (dTMP) activity [28] . All evaluated HSV-1 DNA pol mutants remained sensitive to brivudine.
Analysis of DNA Pol Mutants
The HSV DNA pol ( Figure 1 ) is a multifunctional enzyme of 1235 (HSV-1) and 1240 (HSV-2) amino acids. It possesses polymerase activity (for extension of DNA primer chains), an intrinsic 3′-5′ exonuclease activity (important for correction of misincorporated nucleotides and maintenance of the fidelity and integrity of the newly formed DNA molecules), and 5′-3′ exonuclease and ribonuclease (RNase) H activities [29, 30] . The carboxyl terminal region of the UL30 catalytic subunit interacts with the UL42 accessory protein, which enhances the processivity of DNA replication.
The HSV DNA pol belongs to the B family DNA pols and is composed of 6 structural domains: pre-NH 2 , NH 2 , Palm, 
HSV-2 tenofovir-resistant clones Figure 2 . Resistance properties of plaque-purified herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) clones selected following pressure with tenofovir (TFV) and 6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine (PMEO-DAPy), which bear substitutions in the viral DNA pol. Different plaque-purified viruses bearing specific mutations in the DNA pol genes were compared with wild-type virus using the cytopathic effect reduction assay. At least 3 independent experiments were performed for each plaque-purified virus. Each individual point represents the mean values from independent experiments for 1 particular plaque-purified virus. The data are presented as a dot plot of the 50% effective concentration (EC 50 ) for the drug-resistant clones vs the EC 50 for the wild-type virus. Average (indicated as a horizontal line) ± standard errors (bars) are indicated for the different types of mutants and the wild-type virus. TFV was tested at a maximum concentration of 200 µg/mL and the levels of resistance are expressed as equal to or greater than a certain value when the EC 50 s for the drug were in some antiviral assays higher than the maximum concentration evaluated. The sources of the compounds used in the antiviral assays were as follows: acyclovir [ACV, 9- Fingers, and Thumb domains as well as a 3ʹ→5ʹ exonuclease domain. The HSV DNA pols share 7 clusters of homology conserved among all α-like DNA pols that are numbered in order of decreased percentage of homology (regions I-VII). In addition, a δ-region C, which is homologous to eukaryotic DNA pols δ, is found in herpesvirus DNA pols. The regions I, II, and VII are part of the palm subdomain and together with region V flank the catalytic site that contain the 3 aspartic acid residues (at positions 717, 886, and 888) that are essential for pol activity. Regions III and VI play a role in positioning the template and primer strands. Structure of the active RB69 bacteriophage DNA pol complexed to its substrates (pdb code: 4DU1) was used to build a model of HSV DNA pol in complex with tenofovir-diphosphate (TFV-DP), PMEO-DAPy-DP, acyclovir triphosphate, or foscarnet. Located in the conserved region II of the Palm domain, the HSV-1 A719V change and its counterpart A724V in HSV-2 may impair the correct binding of both TFV-DP and PMEODAPy-DP at the position of the γ-phosphate (Figure 3 ). This can be explained by the bulkier side chain of the valine residue (surface: 155 Å 2 , volume: 140 Å 3 ) in comparison with the alanine residue (surface: 115 Å 2 , volume: 88.6 Å 3 ) modifying the shell of residues surrounding the active site. Similarly, the HSV-1 S724 is also located in the conserved region II of the Palm domain, just below the A719 position. Substitution of a serine residue (surface: 115 Å 2 , volume: 89 Å 3 ) by an asparagine residue (surface: 160 Å 2 , volume: 114.1 Å 3 ) might affect the positioning of A719 among other residues involved directly in the interaction with the nucleoside analogue and therefore the correct binding of PMEO-DAPy-DP. It is worth noting that A719V and S724N in HSV-1 DNA pol and A724V in HSV-2 DNA pol confer also resistance to foscarnet. The position A719 (A724 in HSV-2 DNA pol) and S724 in HSV-1 DNA pol are close to the β-and γ-phosphates of the incoming nucleoside triphosphate, a position that is competitively adopted by foscarnet.
Asparagine 815 (N815) in HSV-1 DNA pol is located in the Finger domain and participates to the interaction with the incoming nucleoside triphosphate. The N815S substitution confers resistance to acyclovir and ganciclovir and hypersensitivity to foscarnet, which may be explained by a better stabilization of foscarnet in the region that binds the pyrophosphate analogue. While N815 interacts with foscarnet indirectly through hydrogen bonds with a water molecule, the substitution by a serine residue reduces the volume of the side chain at position 815, allowing foscarnet to adopt a preferential position between the Fingers and the Palm domains. Figure 4A shows the change in steric hindrance that may occur when the asparagine (yellow dots) is substituted by a serine (red dots) at position 815. In TFV, ADV, PMEDAP, and PMEO-DAPy were tested at a maximum concentration of 200 µg/mL (TFV and ADV) or 50 µg/mL (PMEDAP and PMEO-DAPy), and the levels of resistance are expressed for some of the mutants as equal to or greater than a certain value when the EC 50 s for the drugs were in some antiviral assays higher than the maximum concentration evaluated.
Abbreviations: ACV, acyclovir; ADV, adefovir, 2-phosphonylmethoxyethyl derivative of adenine; BVDU, brivudine; CDV, cidofovir; EC 50 , 50% effective concentration; GCV, ganciclovir; HSV, herpes simplex virus; PCV, penciclovir; PFA, foscarnet; PMEDAP, 2-phosphonylmethoxyethyl derivative of 2,6-diaminopurine; PMEO-DAPy, 6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine; TFV, tenofovir.
contrast, this should have the opposite effect on acyclovir binding as it may reduce the interactions with the phosphates via water molecules ( Figure 4B ).
DISCUSSION
Genital herpes, a highly prevalent sexually transmitted disease, is recognized as one of the most common causes of genital ulcers in developed and developing countries. Infection of ectocervical tissue with HSV-2 results in mucosal immune cell activation increasing the frequency of CD4 + cells [4] . Because infection with HSV-2 has been associated with an increased risk for HIV-1 infection and often worsen the clinical outcome of HIV disease [29, 30] , strategies to prevent transmission of both HIV-1 and HSV are highly desirable.
TFV is considered as one of the leading HIV microbicide candidate. PMEO-DAPy, another ANP with dual anti-HSV and anti-HIV activity, may be considered as a second-line microbicide candidate. By selecting TFV-R and PMEO-DAPy-R viruses, we have now clearly demonstrated that both drugs indeed target the HSV DNA pol explaining their anti-HSV activity. Mutant viruses selected under pressure with these nucleotide analogues were resistant not only to TFV and PMEODAPy but also to foscarnet and acyclovir. Ten (HSV-1) and 18 (HSV-2) DNA pol substitutions, including 14 novel HSV-2 amino acid changes, could be linked to TFV and PMEO-DAPy, with some mutations showing specific drug resistance patterns. Phenotypic analysis of novel HSV DNA pol mutations is crucial to guide therapeutic options in the clinic. Although most of the TFV, ADV, PMEDAP, and PMEO-DAPy were tested at a maximum concentration of 200 µg/mL (TFV and ADV) or 50 µg/mL (PMEDAP and PMEO-DAPy) and the levels of resistance are expressed for some of the mutants as equal to or greater than a certain value when the 50% effective concentrations for the drugs were in some antiviral assays higher than the maximum concentration evaluated.
Abbreviations: ACV, acyclovir; ADV, adefovir, 2-phosphonylmethoxyethyl derivative of adenine; CDV, cidofovir; GCV, ganciclovir; HSV, herpes simplex virus; PCV, penciclovir; PFA, foscarnet; PMEDAP, 2-phosphonylmethoxyethyl derivative of 2,6-diaminopurine; PMEO-DAPy, 6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine; TFV, tenofovir.
a Homologous mutation in HSV-1 linked to drug resistance.
b Fold resistance levels ≥2-fold are highlighted in bold. The amino acid substitutions that were also found in viral clones derived from selective pressure with TFV or PMEO-DAPy are italicized. Underlined substitutions indicate previously undescribed mutations.
HSV acyclovir-resistant infections are due to alterations in the viral enzyme responsible for its activation (ie, TK), a substantial number of DNA pol mutations are found in isolates recovered from patients who fail acyclovir therapy and in individuals who receive foscarnet therapy for acyclovir-resistant infections due to TK alterations [27, [31] [32] [33] .
Mutations emerging under TFV and PMEO-DAPy selective pressure mapped to region II of the viral DNA pol with exception of L802F (located between regions VI and III). These amino acid substitutions were identical to those emerging under pressure with the PME derivatives adefovir and PMEDAP, suggesting that these ANPs interact in a similar manner with the viral enzyme. The greatest number of known mutations conferring drug resistance in HSV DNA pol cluster in the conserved regions II, III, VI, and VII that are directly or indirectly involved in recognition and binding of nucleotides or pyrophosphate and in catalysis [29, 34] . Most of the HSV DNA pol substitutions here reported were found in viruses that remain sensitive to cidofovir. However, the HSV-1 S724N and L802F changes and the HSV-2 I731F substitution were associated with low levels of resistance to cidofovir (2-to 2.8-fold reduced EC 50 ). Therapeutic options in these cases are quite limited, although these viruses retained sensitivity to brivudine and ganciclovir, which represent alternative therapies if the virus still carries a wild-type TK.
Enzymatic assays demonstrated that the active form of the acyclic pyrimidine nucleoside phosphonate PMEO-DAPy (ie, PMEO-DAPy-DP), is recognized by the HIV-1 reverse transcriptase as a purine (eg adenine) nucleotide derivative but not as a pyrimidine [35] . Modeling and docking studies in HIV reverse transcriptase confirmed that PMEO-DAPy-DP fits into the active site of the HIV-1 reverse transcriptase in a similar manner as TFV-DP mimicking an incomplete purine ring. Investigation of the activity of PMEO-DAPy-DP against reverse transcriptases containing the K65R and K70E mutations (that are associated, respectively, with TFV and PMEA resistance) [36, 37] indicated that both mutations conferred resistance to PMEO-DAPy-DP via a similar mechanism, that is, reduced A B Figure 3 . Models of mutant UL30 DNA pols in complex with 6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine diphosphate (PMEO-DAPy-DP) (A) and tenofovir-diphosphate (TFV-DP) (B). Substitutions A719V in herpes simplex virus type 1 (HSV-1) UL30 (A724V in HSV-2 UL30) are represented by yellow (alanine residue) and red dots (valine residue). The colored dots depict the changes in volume of the amino acids side chain. Substitution S724N in HSV-1 UL30 is represented as red stick. The model was built using the structure of RB69 bacteriophage DNA pol (pdb code: 4DU1) and the images were generated using PyMol Delano software.
catalytic efficiency of incorporation [35] . In the present study, we demonstrated using HSV genotypic and phenotypic assays and molecular modeling that PMEO-DAPy, TFV, and the PME derivatives are recognized by the HSV DNA pol similarly.
HSV drug resistance is associated with severe, debilitating mucosal disease and visceral dissemination, constituting an important clinical problem for immunocompromised patients. Among immunocompetent individuals, a low prevalence (range, 0.1%-0.6%) of acyclovir resistance has been reported [24] . In contrast, a prevalence of HSV acyclovir-resistant isolates of up to 36% was found in hematopoietic stem cell transplant recipients [38] and ranging from 3.5% to 7% in HIV patients [24] . While HSV infection in the immunocompetent host commonly requires shortterm anti-HSV therapy, without development of drug resistance, patients with an impaired immune system, being prone to develop drug-resistant infections, generally require long-term anti-HSV therapy to manage persistent infections. Also, and most important, when the host responses are impaired, less pathogenic viruses that would not survive under normal host responses may continue to replicate. Different degrees of pathogenicity in animal models of HSV infection have been described among TK and DNA pol mutants [22, 24, 39] .
Emergence of TFV-R HIV strains isolated in the clinic is rare and is mostly associated with the reverse transcriptase K65R/N and K70E/G/Q changes [36, 37] . However, extensive TFV-R has been reported to emerge after virological failure in a high proportion of patients undergoing a TFV-containing first-line regimen among low-income and middle-income regions in the world [40] . The spectrum of TFV-selected mutations appeared to extend beyond K65R/N and K70E/G/Q as several additional TFV-associated mutations of unknown clinical significance were identified [41] . In our studies, we demonstrated that several substitutions in the HSV DNA pol are associated with TFV-R even if only the DNA mutations L802F (HSV-1) and A724V (HSV-2) changes emerged under TFV pressure.
The use of TFV in combination with a HSV-specific topical antiviral agent to deliver a better prevention of HSV acquisition has not yet been investigated [42] . However, a major drawback in the development of microbicides is poor adherence. To improve delivery systems that minimize the difficulties linked to A B Figure 4 . Models of mutant UL30 DNA pols in complex with foscarnet (A) and acyclo-GMP (acyclovir monophosphate) (B). N815S is represented as yellow dots (N815) and red dots (S815) showing the shift in side chain volume that occupied each residue. The model was built using the structure of RB69 bacteriophage DNA pol (pdb code: 4DU1) and the images were generated using PyMol Delano software. Abbreviations: ACV, acyclovir; FOS, foscarnet.
adherence, intravaginal rings that deliver TFV and the prodrug TDF are currently in early stages of clinical development [43] .
Taking into account that the target of all approved anti-HSV drugs is the DNA pol and that a single mutation in this viral enzyme may confer resistance to many anti-HSV drugs, there is an urgent need to develop novel classes of anti-HSV drugs. The helicase-primase inhibitor ASP2151 (amenamivir) possesses activity against HSV and varicella zoster virus (VZV) [44] . Because of adverse findings in a phase 1 trial, the development of amenamivir was suspended, though clinical development has meanwhile been resumed in Japan for HSV (and VZV) patients with multiple orofacial or genital lesions [45] . Another helicase-primase inhibitor, pritelivir (AIC316, BAY 57-1293), discovered by Bayer [46] , is currently in clinical development by AiCuris. In a phase 2 clinical trial, pritelivir met the primary endpoint by being more effective for suppression of viral shedding compared to valacyclovir, the current standard treatment for genital herpes [47] . Further research is required to assess longer-term efficacy and safety of the drug as well as emergence of resistance following long-term administration. If the safety and efficacy of these helicase-primase inhibitors is confirmed, these drugs could be used not only for the treatment of HSV TK and/or DNA pol mutants but also in PrEP in combination with anti-HIV agents.
In conclusion, our studies clearly demonstrated that TFV and PMEO-DAPy specifically target the HSV DNA pol considering that single substitutions in this viral enzyme were associated with decreased sensitivity to these drugs and, more importantly, the mutant viruses emerging under TFV and PMEO-DAPy presented alterations in the HSV DNA pol.
Notes
